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Abstract We present two cases of recurrent progressive mul-
tifocal leukoencephalopathy (PML) in patients with long
standing virally suppressed human immunodeficiency virus
(HIV) and normal CD4+ T cell count who were taking stable
regimens of highly active antiretroviral therapy (HAART).
This has significant implications for other patients with a past
history of PML, not just those with HIV but also those on
medications such as natalizumab or fumarates.
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Introduction
Progressive multifocal leukoencephalopathy (PML) usually
affects immunocompromised people, such as those with ad-
vanced HIV or a haematological malignancy. A minority of
initial PML diagnoses are in people who are minimally or
mildly immunosuppressed (Berger et al. 1998; Gheuens
et al. 2010). Management is to restore immune function where
possible, and this can result in remission of the PML. The two
cases we describe had initial remission of PML, with subse-
quent development of symptoms and investigation findings
consistent with recurrent PML despite interval maintenance
of minimal immunosuppression and HIV suppression. This
has not previously been described.
Case one
A 49 year old man presented with chronic headache in 2013,
on a background of HIV diagnosed in 1987.
In the early 2000s his CD4+ T cell count was at a lifetime
nadir of 70 cells/μl, plasma HIV RNA 5 ·35 log, and cerebro-
spinal fluid (CSF) 4 · 69 log. At that time he had cognitive
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impairment consistent with HIV associated neurocognitive
disorder (HAND) with an MRI brain showing multifocal grey
and white matter hyperintensities. CSF was normal including
negative PCR for JC virus (JCV) DNA, but a right frontal lobe
biopsy showed oligodendrocyte nuclei with viral inclusions,
prominent reactive astrocytes including bizarre forms, and
was strongly positive for JCV DNA by PCR. HIV associated
encephalitis was also present (Anders et al. 1986).
He commenced HAART for the first time with efavirenz,
lopinavir/ritonavir, lamivudine, and stavudine (the latter two
later switched to raltegravir for tolerability), with consequent
CD4+ T cell count rise to over 300 cells/μl. He was clinically
stable but required institutional care due to poor cognition that
did not improve with HAART.
By 2013 his CD4+ T cell count had been over 500 cells/μl
for 7 years, and HIVRNA had been undetectable for a decade.
Annual MRI brain scans since 2008 (Figs. 1, 2 and 3) showed
progressive white matter atrophy, and since 2010 asymptom-
atic fluctuating contrast enhancement without mass effect, in
both cortical grey and subcortical white matter.
Examination when he presented with headache in 2013
revealed a new right inferior quadrantanopia, preexisting cog-
nitive impairment, mild upper limb action tremor, and im-
paired tandem gait. CD4+ T cell count was 648 cells/μl.
CSF was bland; cryptococcal antigen and HIV RNA were
undetectable. However CSF JCV DNA was detected (below
30 copies/mL, the lower limit of quantification of the assay),
using primers targeting the VP2 gene. The sequenced 131
base pair PCR product was a 93 % match to JCV CPN1 strain
using the Basic Local Alignment Search Tool. MRI brain
showed increased subcortical signal hyperintensity and corti-
cal enhancement in the left posterior temporal lobe extending
Fig. 1 Case one, 2008: Fluid
attenuated inversion recovery
(FLAIR) MRI sequences show-
ing multifocal hyperintensity in
the subcortical U-fibres of the
right basifrontal, right temporal,
and left parieto-occipital regions
(see arrows). The corresponding
T1 post contrast images (lower
row), demonstrate an absence of
enhancement
Fig. 2 Case one, 2011: FLAIR MRI sequences from 2011 again show
hyperintensity in the right basifrontal (see arrows) and left parieto-
occipital regions, now with enhancement on corresponding post contrast
T1 images (lower row) in the right basifrontal region only
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into the parieto-occipital region (Fig. 3). He was diagnosed
with possible recurrent PML.
His headache spontaneously improved only to recur sever-
al months later. An MRI showed new enhancing lesions in the
left temporoparietal grey and subcortical white matter. Serial
MR spectroscopic studies showed increasing choline and
myoinositol in these regions with markedly reduced N-
acetylaspartate implying ongoing gliosis of the subcortical
U-fibres. CSF again showed low JC viral load. A
stereotactic-guided biopsy of the left temporoparietal lesion
was performed within a month of presentation, and repeated
six months later because of the unusual findings, with essen-
tially the same result. The patient has shown no clinical pro-
gression on history or examination since the biopsies. MRI
has not been repeated.
Pathological findings
The leptomeninges were fibrotic with increased vascularity
and patchy chronic inflammation, predominantly T cells.
The cortex displayed prominent reactive gliosis, microglial
activation with multifocal microvascular proliferation, mild
neuronal loss, demyelination with partial axon preservation,
sparse T cells (predominantly CD8+), and some haemosiderin
deposition. There were scattered dysmorphic neurons, some
with enlarged nuclei, marginated chromatin, and peripherally
displaced Nissl substance, and several bizarre astrocytes with
enlarged hyperchromatic pleomorphic nuclei.
There were frequent polyomavirus immunoreactive nuclei
mostly in astrocytes and occasional neurons (SV40 large T
antigen Ab cross-reacting with JCV). Most of the positive
nuclei were not within the areas of demyelination or micro-
vascular proliferation. Classic oligodendroglial inclusions and
microglial nodules, noted in the first biopsy, were not identi-
fied. Immunostains for HIV p24, CMV, Toxoplasma, and
HHV8 were negative.
Case two
A 54-year-old female reported new gait difficulties and un-
steadiness in 2012, with associated recent decline in memory
and language.
In 2006 HIV was diagnosed after presenting with memory
impairment. At the time her nadir CD4+ T cell count was
186 cells/μl with an HIV RNA viral load of 5 · 28 log. An
MRI showed left frontotemporal white matter lesions
(Fig. 4). CSF was qualitatively positive for JCV DNA by
PCR. No quantitative test was performed. She improved sig-
nificantly on a stable regimen of tenofovir, emtricitabine, and
efavirenz. Her HIV RNA was below detection on all subse-
quent testing.
MRI in 2012 showed significant atrophy (predominantly
le f t f ron topar ie ta l ) and new non-enhanc ing T2
hyperintensities in the middle cerebellar peduncles, splenium
and periventricular region (Fig. 5), mainly involving white
matter, but also grey-white matter junction.
CSF was positive for JCV DNA at 2786 copies/ml and
negative for HIV RNA. She had a detectable immune re-
sponse to JCV mediated by both CD4+ and CD8+ T cells.
Although her CD4+ T cell count was 676 cells/μl and HIV
RNA undetectable, her medications were changed to abacavir,
emtricitabine, etravirine, raltegravir, and maraviroc to opti-
mise brain penetration. The right frontal region was biopsied.
Mirtazapine was trialled to no avail, and she deteriorated and
died seven months after the biopsy.
Pathological findings
The biopsy showed marked reactive white matter gliosis, and
acute demyelination. There were scattered large, atypical nu-
clei, some suggestive of viral inclusions. Immunostaining
using SV40 Ab highlighted scattered positive cells, mostly
oligodendrocytes in the white matter edge of the demyelinat-
ing lesions, and the grey-white junction.
Fig. 3 Case one, 2013: FLAIR hyperintensity has increased in the left
parieto-occipital region (see arrows, top images), with new gyriform
enhancement (see arrows, bottom images) on corresponding pre-
contrast FLAIR sequences. The right basifrontal contrast enhancement
has shown a complete resolution
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HIV encephalitis was present with marked microglial acti-
vation (highlighted with CD45 immunostaining) occasional
microglial nodules and reactive gliosis withmild neuronal loss
(highlighted with NeuN). Additionally there was mild chronic
inflammation, with perivascular and scattered parenchymal
CD4+, CD8+, and CD3+ Tcells which could not be accurate-
ly quantified because of the limited tissue available for study.
Discussion
These cases demonstrate three novel important points. First,
PMLmay recur years after the initial illness, despite normal or
near-normal immune function. Second, recurrence of clinical
PMLmay be presaged byMRI brain changes. Third, the MRI
changes may fluctuate over time.
We believe JCV caused the clinical, radiological, and neu-
ropathological features described. In both cases, clinical and
MRI findings were compatible with PML (Brew et al. 2010;
Gheuens et al. 2013), although in the first case, the fluctuating
cortical gyriform enhancement is unusual. The pathology was
also consistent with PML except the microvascular prolifera-
tion. Hyperperfusion within and at the edge of PML lesions
has previously been demonstrated, however it was unclear
whether this was due to microvascular proliferation or vaso-
dilation (Khoury et al. 2013).
SV40 staining was seen in cortical neurons in the first case.
This has been described in up to half of patients with classic
PML, within areas of cortical demyelination or in isolation
(Wuthrich and Koralnik 2012). Our patient’s biopsy showed
cortical demyelination with infection of astrocytes and neu-
rons and some inflammation. This is consistent with cortical
involvement by PML, which may explain the cortical
gyriform enhancement seen on MRI.
Most importantly, JCV DNAwas detected in the CSF and
brain of both patients by several techniques. No alternative
cause was found. Autopsies of HIV infected patients have
previously shown Bburnt out^ cerebral lesions from long term
PML without evidence of JCV activity (Gray et al. 2003).
There is no clear reason why these two patients in particular
had PML recurrence; hypotheses include an undetermined
host genetic predisposition, HIV-accelerated age related im-
mune senescence, or viral factors such as development of a
mutation in a JCV quasi-species.
JCV DNA has previously been found in low copy number
in CSF up to one half of natalizumab associated PML patients
months (and in one case three years) after PML stabilization
off natalizumab (Ryschkewitsch et al. 2010). However those
patients had no definite evidence of clinically active disease in
contradistinction to our two patients.
These cases therefore have significant implications for the
prognosis and management of patients with JCV CNS infec-
tion. Although PML often improves with HAART, our
Fig. 4 Case two, 2006: FLAIR MRI sequences demonstrating multiple poorly defined bright foci in the central and periventricular white matter, with
subcortical U-fibre involvement (see arrows) in the frontoparietal region
Fig. 5 Case two, 2012: FLAIR MRI sequences showing new lesions in
the posterior fossa (see arrow) and an increase in the number of lesions in
the high frontoparietal white matter bilaterally (see arrows). There was
also increased cerebral atrophy. There was no mass effect, perilesional
oedema, or enhancement after contrast administration (not shown)
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findings suggest this population, and others with PML, may
be at risk of PML recurrence. Serial monitoring clinically and
by MRI may allow early identification. There is no proven
PML therapy besides immune reconstitution (Tan et al.
2009; Koralnik 2006), which is of particular concern given
that our patients were not immunosuppressed anymore. How-
ever, should PML recurrence be identified in other groups
such as natalizumab or fumarates-treated patients, current
immunomodulating and immunosuppressive therapies may
need to be reconsidered.
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